International Journal of Breast Cancer最新文献

{"title":"PI3K Mutation Profiles on Exons 9 (E545K and E542K) and 20 (H1047R) in Mexican Patients With HER-2 Overexpressed Breast Cancer and Its Relevance on Clinical-Pathological and Survival Biological Effects.","authors":"T Nieto-Coronel, Ortega-Gómez Alette, R Yacab, E A Fernández-Figueroa, C Lopez-Camarillo, L Marchat, H Astudillo-de la Vega, E Ruiz-Garcia","doi":"10.1155/2024/9058033","DOIUrl":"https://doi.org/10.1155/2024/9058033","url":null,"abstract":"<p><p><b>Background</b>: Trastuzumab resistance is associated with overexpressing the human epidermal growth factor receptor 2 (HER-2), which results from the altered phosphoinositide 3-kinase (PI3K) pathway in breast cancer patients. <b>Objective</b>: We quantified the frequency of PI3K enzyme single and double-point mutations in Mexican patients with HER-2 overexpressing breast cancer and its association with clinical-pathological variables. <b>Methods</b>: We embedded HER-2 breast samples in paraffin from 60 patients, extracted their DNA, and evaluated PI3K mutations in 49 HER-2-positive breast tumors. We focused on mutations for one exon 20 (H1047R) and two exon 9 PI3K (E545K, E542K) hotspots and characterized them as single and double-point mutations. The mean patient follow-up was 86 months. <b>Results</b>: Of 49 patients who tested positive for HER-2 breast cancer, 14.28% showed mutations in PI3K, 71.42% single-point, and 28.56% double-point mutations. We found single-point mutations in H1047R (42.85%) and E545K (28.57%). Only two patients exhibited double-point mutations: one in E542K/E545K and another in H1047R/E545K (14.28% each). Although we observed lower survival in patients with mutations in PI3K, we did not find a significant association between these factors (<i>p</i> = 0.191). However, single and double-point mutations in PI3K were significantly associated with the clinical stages of diagnosis and tumor size (<i>p</i> = 0.027 and <i>p</i> = 0.04, respectively). <b>Conclusion</b>: Single and double-point mutations in PI3K are related to tumor size and advanced clinical-pathological traits in Mexican patients with HER-2 overexpression, and future molecular studies are necessary to understand these findings.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11496583/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142510156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated With Uptake of Breast Cancer Screening Among Catholic Nuns in Lake Zone, Tanzania.","authors":"Gotfrida Marandu, Rose Laisser, Kija Malale, Peter Rambau","doi":"10.1155/2024/5024392","DOIUrl":"10.1155/2024/5024392","url":null,"abstract":"<p><p><b>Background:</b> Breast cancer is the most common cancer among women worldwide. Breast cancer screening programs are widely promoted because of their effectiveness in the early detection of cancer. However, a significant proportion of eligible Catholic nuns in the Lake Zone of Tanzania remain underscreened. This study is aimed at investigating the factors associated with breast cancer screening uptake among Catholic nuns in Lake Zone, Tanzania. <b>Methods:</b> This was a cross-sectional study design among 385 catholic nuns. Simple random sampling was deployed to enrolled catholic nuns, the ODK collect v2023.2.4 was electronically used to collect data. Binary logistic regression was used to assess the factors associated with the uptake of breast cancer screening. Statistical analysis was performed using STATA 18.0, with a significance level set at a <i>p</i> value less than 0.05. <b>Result:</b> The prevalence uptake of breast cancer screening (i.e., breast self-examination, clinical examination, or mammography examination) was 64% (<i>n</i> = 247, 95% CI, 59.3%-68.9%). A total of 57.4% had inadequate knowledge on the uptake of breast cancer screening (<i>n</i> = 221, 95% CI, 52.4%-62.4%). Also, the study found that 61.3% (95% CI, 56.4%-66.2%) of Catholic Nuns have negative attitudes towards the uptake of self-breast examination among Catholic nuns. The findings revealed that 55.6% (<i>n</i> = 133, 95% CI, 50.6%-60.6%) and 52.7% (<i>n</i> = 52.7%, 95% CI, 47.7%-57.7%) of Catholic nuns negatively accept breast cancer screening and self-breast examination, respectively. Nuns aged above 60 years were less likely to not perform BCS with a COR of 0.62 (95% CI, 0.39-0.97). Also, Catholic nuns who are in the nonhealth field are more likely to not perform BCS with a COR of 1.71 (95%, 1.07-2.74). Likewise, Catholic nuns who had negative acceptability of the Self-breast examination were more likely to not perform BCS with an AOR of 1.65 (95% CI, 1.07-2.55). <b>Conclusion:</b> A study found a low uptake of breast cancer screening among Catholic nuns. This highlights the need for breast health intervention programs within religious congregations to address misconceptions and promote early detection.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11490345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142477393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triple-Negative Breast Cancer: Tumor Immunogenicity and Beyond.","authors":"Elio Ibrahim, Ernest Diab, Rony Hayek, Karim Hoyek, Hampig Kourie","doi":"10.1155/2024/2097920","DOIUrl":"https://doi.org/10.1155/2024/2097920","url":null,"abstract":"<p><p>Triple-negative breast cancer (TNBC) is a breast malignancy with a poor prognosis and limited therapeutic options. Many studies show that TNBC exhibits heterogeneity across clinical, histopathological, and molecular levels. In this review, we discuss the immunogenic features of TNBC with a focus on immunotherapy and the current standard of care in the neoadjuvant, adjuvant, and metastatic setting. In addition, we address the ongoing research on immunotherapy, antibody-drug conjugates (ADCs), poly ADP-ribose polymerase (PARP) inhibitors, and future challenges in the treatment of this entity.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11469932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142477394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Awareness, Attitude, and Practices of Breast Cancer Screening and Prevention Among General Public and Physicians in Pakistan: A Nation With the Highest Breast Cancer Incidence in Asia.","authors":"Adeel Aslam, Asma Ghulam Mustafa, Ali Hussnain, Hafsa Saeed, Fatima Nazar, Maha Amjad, Ayesha Mahmood, Atika Afzal, Anam Fatima, Doaa Kamal Alkhalidi","doi":"10.1155/2024/2128388","DOIUrl":"10.1155/2024/2128388","url":null,"abstract":"<p><p><b>Introduction:</b> Breast cancer is a global health challenge with significant mortality, affecting millions worldwide. The current study is aimed at evaluating awareness and practices related to breast cancer screening, prevention, and treatment among the general public and physicians in Lahore, Pakistan, which has a significant incidence of breast cancer. <b>Methodology:</b> The current study adopted a cross-sectional study design conducted in Lahore, Pakistan, between March and August 2023, among 404 participants from the general public and 240 physicians. Data collection and evaluation involved the use of validated questionnaires, and both descriptive and inferential statistics were performed using SPSS Version 25. <b>Result:</b> In Lahore, Pakistan, breast cancer awareness among the public was low, with 80.2% unaware of its global prevalence, 65.3% believing not everyone is at risk, and only 42.1% recognizing symptoms. Females showed greater awareness (OR: 1.020, CI: 0.617-1.686, <i>p</i> = 0.002) and positive attitudes (OR: 2.711, CI: 1.478-6.478, <i>p</i> = 0.045), while the 18-29 age group had higher odds of positive practices (OR: 4.317, CI: 2.678-5.956, <i>p</i> = 0.004). Educational attainment significantly influences knowledge and attitudes. Only 13.9% practiced self-examination. Among physicians, 88.8% were confident in screenings, but patient fear (42.9%) and financial barriers (79.2%) hindered action. Physicians with FCPS qualifications had higher odds of awareness (OR: 1.550, CI: 1.130-2.117, <i>p</i> = 0.007), attitudes (OR: 1.500, CI: 1.050-2.150, <i>p</i> = 0.025), and practices (OR: 1.470, CI: 1.070-2.017, <i>p</i> = 0.020). Those with 11-20 years of experience also showed better awareness (OR: 1.400, CI: 1.050-1.868, <i>p</i> = 0.022) and attitudes (OR: 1.450, CI: 1.045-2.018, <i>p</i> = 0.029). <b>Conclusion:</b> In conclusion, breast cancer awareness among the general public is limited, highlighting the need for tailored education programs. Although most physicians show high awareness, challenges in patient communication and barriers, such as fear and financial constraints, must be addressed to improve screening uptake. These findings emphasize the importance of targeted interventions to enhance public awareness, screening practices, and physician-patient communication.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11455591/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Tissue Eosinophilic Infiltration in Invasive Mammary Carcinoma.","authors":"Farah Falah Hasan, Mohammed Haider Fadhil, Zainab Khalid Almukhtar","doi":"10.1155/2024/1514147","DOIUrl":"https://doi.org/10.1155/2024/1514147","url":null,"abstract":"<p><p><b>Background:</b> Stromal inflammatory cells in malignant tissue have recently gained increasing interest. Unlike the extensive research on tumor-infiltrating lymphocytes, published data about tumor-infiltrating eosinophils in breast cancer are scarce. Furthermore, similar studies have yet to be conducted in Iraq. <b>Aims</b>: The objective of this study is to examine the presence of eosinophilic infiltration by direct visualization using light microscopy and to analyze its relationship with other histological parameters in a group of Iraqi women diagnosed with invasive mammary cancer. <b>Methods and material</b>: A retrospective study enrolled 90 histological samples of invasive mammary carcinoma provided by core needle biopsy from a single center, together with their immunohistochemical results for ER and HER2-NEU. Data reviewing, direct morphological visualizations, and counting eosinophilic infiltration in tissue sections were done by two independent pathologists using light microscopy. The results were statistically correlated with the grade, ER, HER2-NEU, calcification, and axillary lymph node status at presentation. <b>Results</b>: Out of the entire sample size (90), 40 (44%) showed the presence of eosinophilic infiltration in the tissue, both intratumoral and stromal. Further analysis revealed that most eosinophilic infiltrates had an intermediate score (4-19) per 10 consecutive high-power fields. A strong and meaningful statistical relationship was seen between tissue eosinophilic infiltration and HER2/NEU status. A statistically insignificant correlation was seen between tissue eosinophilic infiltration and histological grade, ER receptor status, calcification, and axillary lymph node status at presentation. <b>Conclusions</b>: Eosinophils are tumor-infiltrating cells in breast cancer, both intratumoral and stromal. The presence of tissue eosinophilic infiltration can predict HER2/NEU negativity in breast cancer.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11410403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metformin as a Potential <i>In Vitro</i> Anticancer Modulator of Adenosine Monophosphate Kinase: A Review.","authors":"A G R Greshamali Jinadasa, H M Kasuni Akalanka, N D Amal Wageesha, Sagarika Ekanayake","doi":"10.1155/2024/1094274","DOIUrl":"10.1155/2024/1094274","url":null,"abstract":"<p><p>Metformin (MET) is the commonly prescribed hypoglycemic agent used in the treatment of type 2 diabetes mellitus (DM). Pleiotropic effects of MET are emerging as a medication for other diseases including breast cancer (BC). Therefore, a literature review was conducted to investigate whether the anticancer effects of MET are mediated through adenosine monophosphate kinase (AMPK). This review assessed published data focusing on studies where BC cell lines were treated with MET to explore its potential anticancer effects via AMPK on BC cells. The published data reveals that activated AMPK induces anticancer effects primarily by suppressing cell proliferation, induction of apoptosis, and cell cycle arrest, inhibition of metastasis and invasion, alteration of tumor microenvironment, and downregulation of tumorigenesis. In addition, MET was observed to induce AMPK-mediated effects when combined with other drugs. Further studies on assessing the potential use of MET alone or in combination with other drugs would pave the way to design new treatment strategies for BC.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380709/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer.","authors":"Iris Otoya, Natalia Valdiviezo, Zaida Morante, Cindy Calle, Yomali Ferreyra, Norma Huarcaya-Chombo, Gabriela Polo-Mendoza, Carlos Castañeda, Tatiana Vidaurre, Silvia P Neciosup, Mónica J Calderón, Henry L Gomez","doi":"10.1155/2024/9551710","DOIUrl":"10.1155/2024/9551710","url":null,"abstract":"<p><p><b>Purpose:</b> In Peru, breast cancer (BC) stands as the most predominant malignancy neoplasm among women. Trastuzumab has marked a significant milestone in the management of this disease. It has been shown to improve prognosis in human epidermal growth factor receptor 2 (HER2)-expressing female patients, but its repercussions and efficacy are yet to be analyzed in a context with limited resources. <b>Methods:</b> The study population is made of woman patients aged 18 years and older diagnosed with HER2-positive BC at Instituto Nacional de Enfermedades Neoplásicas (INEN, Lima, Peru) during 2019-2021 and treated with at least one dose of subcutaneous trastuzumab. We reviewed medical records to register treatment characteristics, adverse events (AEs), disease progression, and survival status. We considered a median follow-up time of 36 and 45 months for progression and survival status. <b>Results:</b> The majority of patients were over 50 years old (54.29%). Tumor size averaged 19.7 ± 16.1 mm. Lymph nodes were present in 44.78% of patients. Most patients received adjuvant chemotherapy (63.8%) as first-line treatment. Descriptive analyses of treatment outcomes revealed a 30% toxicity rate, primarily attributed to arthralgia (47.62%), followed by diarrhea, fatigue, and injection site reactions, with relatively lower discontinuation rates compared to larger scale studies. Differences in demographic, clinical, and treatment characteristics were not statistically significant concerning the emergence of AEs (<i>p</i> > 0.05). Progression appeared in nine patients, and the overall survival (OS) rate stood at 98.6% and 92.8%, respectively, during a median follow-up of 36 and 45 months. <b>Conclusion:</b> The research suggests that subcutaneous trastuzumab is comparable in effectiveness and safety to the intravenous administration. Regional-specific studies may provide valuable insights into demographic factors influencing treatment outcomes in Peru or other countries. Furthermore, it could represent a more accessible alternative, potentially enhancing patient adherence and optimizing healthcare resource logistics.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11222001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of Intraoperative Radiotherapy in Early-Stage Breast Cancer Patients in a Clinical Setting.","authors":"Ao Wang, Elchanan Quint, Ivan Kukeev, Ravit Agassi, Olga Belochitski, Gay Barski, Julie Vaynshtein","doi":"10.1155/2024/5551907","DOIUrl":"10.1155/2024/5551907","url":null,"abstract":"<p><p><b>Background:</b> Intraoperative radiation therapy (IORT) has gained popularity in recent years as an alternative to external beam whole breast radiation therapy (WBRT) for early-stage breast cancer. Here, we report 43-month recurrence and survival outcomes in a multiethnic cohort treated with IORT in a clinical context. <b>Method:</b> Two hundred and eleven patients with low-risk features were treated with IORT for early-stage breast cancer from 2014 to 2021. Selection criteria were based on Group Europeen de Curietherapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) guidelines: preferably unifocal intraductal carcinoma (IDC), aged > 50, tumor size ≤ 2.0 cm, and without lymph node involvement. All patients received 20 Gy of radiation dose during the lumpectomy. Information on patient and tumor characteristics was collected. <b>Results:</b> The mean age of this cohort was 67.5 years; 95.2% of patients are Jewish, and the rest are Bedouins (4.7%). Most tumors were intraductal carcinoma (97.2%) and stage 1 (94.8%). The mean follow-up time was 43.4 months. Bedouins had larger tumor sizes (mean 1.21 vs. 1.13 cm) and were younger at diagnosis than Jewish patients (mean 65.4 vs. 67.6 years), although the differences are not significant. The overall recurrence rate was 1.4%. One case of local recurrence (0.5%) and two cases of metastasis (0.9%) were observed during the study period. One patient died from metastasis. <b>Conclusion:</b> Our findings suggest that IORT in selected low-risk patients can achieve an excellent prognosis with low rates of recurrence and metastasis.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11199062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141451887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights Into the Emerging Entity of HER2-Low Breast Cancer.","authors":"Georges El Haddad, Ernest Diab, Michel Hajjar, Maroun Aoun, Farid Mallat, Ziad Zalaquett, Hampig-Raphael Kourie","doi":"10.1155/2024/2853007","DOIUrl":"10.1155/2024/2853007","url":null,"abstract":"<p><p>Human epidermal growth factor receptor 2 (HER2)-low breast cancer (BC) is a subtype of BC that has been recently recognized as a separate clinical entity with distinct clinical and molecular characteristics. It is defined by a low level of HER2 protein expression, which distinguishes it from other more aggressive BC subtypes. Early studies suggest that it may have a more favorable prognosis than HER2-positive BC, as it is less likely to spread to other parts of the body and may be more responsive to standard BC treatments such as chemotherapy, radiation therapy, and hormone therapy. Given the relative new emergence of HER2-low BC, there is still much to be learned about this subtype; ongoing research is focused on identifying the underlying genetic mutations that contribute to HER2-low BC as well as developing targeted therapies that can improve outcomes for patients with this disease. This review is aimed at summarizing the current clinical knowledge on HER2-low BC, with the aim of creating a better understanding of this entity and paving the way for potential interventions and a new standard of care.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Immunohistochemical Analysis of Epithelial-Mesenchymal Transition Biomarkers in the Invasive Micropapillary Cancer of the Breast.","authors":"Ozden Oz, Funda Alkan Tasli, Resmiye Irmak Yuzuguldu, Baha Zengel, Demet Kocatepe Cavdar, Merih Guray Durak, Raika Durusoy","doi":"10.1155/2024/2350073","DOIUrl":"10.1155/2024/2350073","url":null,"abstract":"<p><p><b>Background</b>: Invasive micropapillary carcinoma (IMPC) of the breast is commonly associated with a poor prognosis due to its high incidence of lymphovascular invasion and lymph node metastasis (LNM). Our study is aimed at investigating the prognostic significance of the expressions of E-cadherin (E-cad), N-cadherin (N-cad), CD44s, and <i>β</i>-catenin (<i>β</i>-cat). In addition, it is aimed at deciphering the consistency of these markers between the IMPC, the invasive breast carcinoma, no-special type (IBC-NST), and LNM components in the same IMPC cases. <b>Methods:</b> Sixty-two IMPC cases with LNM from 1996 to 2018 were analyzed. Immunohistochemical staining was performed separately on the three regions for each patient. Statistical analyses included Kaplan-Meier, Cox regression, and McNemar's statistical tests. <b>Results:</b> Loss of CD44 expression in IMPC, IBC-NST, and LNM areas was associated with poor prognosis in overall survival (OS) (<i>p</i> = 0.010, <i>p</i> < 0.0005, <i>p</i> = 0.025). Loss of CD44 expression in the IBC-NST, gain of N-cad expression in the IMPC, and loss of <i>β</i>-cat expression in the LNM areas were indicators of poor prognosis in disease-free survival (DFS) (<i>p</i> = 0.005, <i>p</i> = 0.041, <i>p</i> = 0.009). <b>Conclusion:</b> Our evaluation of this rare subtype, focusing on the expression of key epithelial-mesenchymal transition (EMT) molecules, revealed that it shares characteristics with the IBC-NST component within mixed tumors. Notably, contrary to expectations, a reduction in CD44 expression was found to adversely affect both OS and DFS. By conducting staining procedures simultaneously across three regions within the same patient, a novel approach has provided valuable insights into the mechanisms of EMT.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11189676/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141433042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}